Red Biotechnology Market, By Product Type (Biopharmaceuticals, Biosimilars, Gene Therapy, Tissue Engineering, Cell Therapy), By Application (Drug Discovery & Development, Animal Biotechnology, Environmental Biotechnology, Medical Biotechnology, Industrial Biotechnology, Agricultural Biotechnology, Others), By End User (Pharmaceutical & Biopharmaceutical Companies, Research Institutes, Biotechnology Industry, Hospitals & Diagnostic Centers, Academic Institutions), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Nov 2023

Code : CMI6416

Pages :150

Formats :

Excel and PDF

Industry : Biotechnology

Market News

Global Red Biotechnology Market- Recent Developments

New Product Launches

On April 27, 2023, Pfizer Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved PREVNAR 20(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR
In September 2021, BDR Pharmaceuticals, a pharmaceutical company launched generic Cabozantinib that is used for the treatment of various types of cancer in India. Cabozantinib is used for the treatment of metastatic medullary thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma.
In May 2020, U.S. Food and Drug Administration approved atezolizumab in combination with bevacizumab manufactured by Genentech Inc, a biotechnology corporation, for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy
In March 2020, U.S. Food and Drug Administration granted accelerated approval to the combination of nivolumab and ipilimumab manufactured by Bristol-Myers Squibb Co., a global biopharmaceutical company, for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

Acquisition and Partnerships

On January 9, 2023, Ipsen, a France-based biopharmaceutical company, and Albireo, a biotech company providing pharmaceutical products and services, announced that both had signed a binding merger agreement, under which Ipsen would acquire Albireo, a pioneer in the development of bile-acid modulators, for the treatment of cholestatic liver disorders in both children and adults
In November 2022, TriSalus Life Sciences, a privately held oncology therapeutics company, announced that it had entered into a definitive merger agreement with MedTech Acquisition Corporation, a publicly traded special purpose acquisition company
In August 2022, GSK plc, a pharmaceutical company, announced that it had completed the acquisition of Affinivax, Inc (Affinivax), a U.S.-based clinical-stage biopharmaceutical company. Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
In June 2020, Gavi, the Vaccine Alliance’s, an independent multilateral funding organization, announced a new supply agreement with Serum Institute of India, Pvt. Ltd. (SIIPL), a pharmaceutical company, under the Advance Market Commitment (AMC) for its World Health Organization prequalified pneumococcal conjugate vaccine (PCV), PNEUMOSIL, to fight against pneumococcal disease, a leading cause of severe childhood pneumonia, sepsis, and meningitis in the low and middle income countries such as India, Bangladesh, and others